167 related articles for article (PubMed ID: 35412513)
1. Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome.
Ballou S; Haas JW; Iturrino J; Nee J; Kirsch I; Rangan V; Cheng V; Lembo A; Kaptchuk TJ; Kelley JM
Psychosom Med; 2022 Jul-Aug 01; 84(6):738-746. PubMed ID: 35412513
[TBL] [Abstract][Full Text] [Related]
2. Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.
Lembo A; Kelley JM; Nee J; Ballou S; Iturrino J; Cheng V; Rangan V; Katon J; Hirsch W; Kirsch I; Hall K; Davis RB; Kaptchuk TJ
Pain; 2021 Sep; 162(9):2428-2435. PubMed ID: 33605656
[TBL] [Abstract][Full Text] [Related]
3. Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial.
Ballou S; Kaptchuk TJ; Hirsch W; Nee J; Iturrino J; Hall KT; Kelley JM; Cheng V; Kirsch I; Jacobson E; Conboy L; Lembo A; Davis RB
Trials; 2017 May; 18(1):234. PubMed ID: 28545508
[TBL] [Abstract][Full Text] [Related]
4. Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study.
Haas JW; Ongaro G; Jacobson E; Conboy LA; Nee J; Iturrino J; Rangan V; Lembo A; Kaptchuk TJ; Ballou S
BMC Psychol; 2022 Feb; 10(1):20. PubMed ID: 35120572
[TBL] [Abstract][Full Text] [Related]
5. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial.
Nurko S; Saps M; Kossowsky J; Zion SR; Di Lorenzo C; Vaz K; Hawthorne K; Wu R; Ciciora S; Rosen JM; Kaptchuk TJ; Kelley JM
JAMA Pediatr; 2022 Apr; 176(4):349-356. PubMed ID: 35099543
[TBL] [Abstract][Full Text] [Related]
6. Examining the mediational role of psychological flexibility, pain catastrophizing, and visceral sensitivity in the relationship between psychological distress, irritable bowel symptom frequency, and quality of life.
Cassar GE; Knowles S; Youssef GJ; Moulding R; Uiterwijk D; Waters L; Austin DW
Psychol Health Med; 2018 Dec; 23(10):1168-1181. PubMed ID: 29882424
[TBL] [Abstract][Full Text] [Related]
7. Altered attentional control linked to catastrophizing in patients with irritable bowel syndrome.
Henrich JF; Martin M
Br J Health Psychol; 2018 Sep; 23(3):612-629. PubMed ID: 29573051
[TBL] [Abstract][Full Text] [Related]
8. Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome.
Wang RS; Lembo AJ; Kaptchuk TJ; Cheng V; Nee J; Iturrino J; Rao M; Loscalzo J; Silvester JA; Hall KT
Front Pain Res (Lausanne); 2021; 2():775386. PubMed ID: 35295415
[No Abstract] [Full Text] [Related]
9. Multiple psychological factors predict abdominal pain severity in children with irritable bowel syndrome.
Hollier JM; van Tilburg MAL; Liu Y; Czyzewski DI; Self MM; Weidler EM; Heitkemper M; Shulman RJ
Neurogastroenterol Motil; 2019 Feb; 31(2):e13509. PubMed ID: 30549152
[TBL] [Abstract][Full Text] [Related]
10. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study.
Azpiroz F; Dubray C; Bernalier-Donadille A; Cardot JM; Accarino A; Serra J; Wagner A; Respondek F; Dapoigny M
Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27477485
[TBL] [Abstract][Full Text] [Related]
11. Anti-irritable Bowel Syndrome Syrup Improves Constipation-Predominant Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial.
Pazhouh HK; Hosseini SMA; Taghipour A; Hamedi S; Noras M
Chin J Integr Med; 2020 Oct; 26(10):729-735. PubMed ID: 32623701
[TBL] [Abstract][Full Text] [Related]
12. Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model.
van Tilburg MA; Palsson OS; Whitehead WE
J Psychosom Res; 2013 Jun; 74(6):486-92. PubMed ID: 23731745
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial.
Seddighnia A; Tadayon Najafabadi B; Ghamari K; Noorbala AA; Ebrahimi Daryani N; Kashani L; Akhondzadeh S
J Clin Pharm Ther; 2020 Feb; 45(1):97-104. PubMed ID: 31486103
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.
Schmulson MJ; Chiu-Ugalde J; Sáez-Ríos A; López-Colombo A; Mateos-Pérez GJ; Remes-Troche JM; Sobrino-Cossio S; Soto-Pérez JC; Tamayo de la Cuesta JL; Teramoto-Matsubara OT; López-Alvarenga JC
J Clin Gastroenterol; 2020 Apr; 54(4):e30-e39. PubMed ID: 31385885
[TBL] [Abstract][Full Text] [Related]
16. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients.
Ludidi S; Jonkers DM; Koning CJ; Kruimel JW; Mulder L; van der Vaart IB; Conchillo JM; Masclee AA
Neurogastroenterol Motil; 2014 May; 26(5):705-14. PubMed ID: 24588932
[TBL] [Abstract][Full Text] [Related]
18. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L
World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816
[TBL] [Abstract][Full Text] [Related]
19. A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome.
Gerson CD; Gerson MJ; Chang L; Corazziari ES; Dumitrascu D; Ghoshal UC; Porcelli P; Schmulson M; Wang WA; Zali M
Neurogastroenterol Motil; 2015 Apr; 27(4):490-500. PubMed ID: 25817055
[TBL] [Abstract][Full Text] [Related]
20. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.
Alderson SL; Wright-Hughes A; Ford AC; Farrin A; Hartley S; Fernandez C; Taylor C; Ow PL; Teasdale E; Howdon D; Guthrie E; Foy R; Ridd MJ; Bishop FL; Muir D; Chaddock M; Herbert A; Cooper D; Gibbins R; Newman S; Cook H; Longo R; Everitt H
Trials; 2022 Jul; 23(1):552. PubMed ID: 35804433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
